BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
55.59
+2.85 (5.40%)
May 29, 2026, 12:06 PM EDT - Market open
BioMarin Pharmaceutical Stock Forecast
Stock Price Forecast
According to 26 analysts polled by S&P Global, BioMarin Pharmaceutical stock has a consensus rating of "Buy" and an average price target of $87.85. The average 1-year stock price forecast is 58.03% higher than the current stock price, while the lowest is $50 (-10.06%) and the highest is $120 (+115.87%).
Price Target: $87.85 (+58.03%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for BioMarin Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 14 | 14 | 14 | 14 | 15 |
| Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Hold | 7 | 6 | 5 | 5 | 5 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 24 | 24 | 23 | 23 | 24 | 26 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel Nicolaus | Stifel Nicolaus | Hold Maintains $68 | Hold | Maintains | $68 | +22.32% | May 24, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $116 → $111 | Buy | Maintains | $116 → $111 | +99.68% | May 22, 2026 |
| Raymond James | Raymond James | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 22, 2026 |
| H.C. Wainwright | H.C. Wainwright | Hold Reiterates $50 | Hold | Reiterates | $50 | -10.06% | May 22, 2026 |
| Jefferies | Jefferies | Buy Maintains $104 | Buy | Maintains | $104 | +87.08% | May 21, 2026 |
Financial Forecast
Revenue This Year
3.95B
from 3.22B
Increased by 22.53%
Revenue Next Year
4.53B
from 3.95B
Increased by 14.67%
EPS This Year
3.97
from 1.80
Increased by 120.14%
EPS Next Year
5.78
from 3.97
Increased by 45.42%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 4.1B | 4.9B | ||||||
| Avg | 3.9B | 4.5B | ||||||
| Low | 3.7B | 4.1B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 27.7% | 24.6% | ||||||
| Avg | 22.5% | 14.7% | ||||||
| Low | 15.0% | 4.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 5.21 | 9.16 | ||||||
| Avg | 3.97 | 5.78 | ||||||
| Low | 3.14 | 3.03 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 188.6% | 130.5% | ||||||
| Avg | 120.1% | 45.4% | ||||||
| Low | 73.8% | -23.8% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.